Terlipressin versus Norepinephrine in the Treatment of Hepatorenal Syndrome: A Systematic Review and Meta-Analysis

Carregando...
Imagem de Miniatura
Citações na Scopus
107
Tipo de produção
article
Data de publicação
2014
Título da Revista
ISSN da Revista
Título do Volume
Editora
PUBLIC LIBRARY SCIENCE
Citação
PLOS ONE, v.9, n.9, article ID e107466, 7p, 2014
Projetos de Pesquisa
Unidades Organizacionais
Fascículo
Resumo
Background: Hepatorenal syndrome (HRS) is a severe and progressive functional renal failure occurring in patients with cirrhosis and ascites. Terlipressin is recognized as an effective treatment of HRS, but it is expensive and not widely available. Norepinephrine could be an effective alternative. This systematic review and meta-analysis aimed to evaluate the efficacy and safety of norepinephrine compared to terlipressin in the management of HRS. Methods: We searched the Medline, Embase, Scopus, CENTRAL, Lilacs and Scielo databases for randomized trials of norepinephrine and terlipressin in the treatment of HRS up to January 2014. Two reviewers collected data and assessed the outcomes and risk of bias. The primary outcome was the reversal of HRS. Secondary outcomes were mortality, recurrence of HRS and adverse events. Results: Four studies comprising 154 patients were included. All trials were considered to be at overall high risk of bias. There was no difference in the reversal of HRS (RR = 0.97, 95% CI = 0.76 to 1.23), mortality at 30 days (RR = 0.89, 95% CI = 0.68 to 1.17) and recurrence of HRS (RR = 0.72; 95% CI = 0.36 to 1.45) between norepinephrine and terlipressin. Adverse events were less common with norepinephrine (RR = 0.36, 95% CI = 0.15 to 0.83). Conclusions: Norepinephrine seems to be an attractive alternative to terlipressin in the treatment of HRS and is associated with less adverse events. However, these findings are based on data extracted from only four small studies.
Palavras-chave
Referências
  1. Alessandria C, 2007, J HEPATOL, V47, P499, DOI 10.1016/j.jhep.2007.04.010
  2. Angeli P, 2012, J HEPATOL, V57, P1135, DOI 10.1016/j.jhep.2012.06.024
  3. Arroyo V, 2011, NAT REV NEPHROL, V7, P517, DOI 10.1038/nrneph.2011.96
  4. Arroyo V, 1996, HEPATOLOGY, V23, P164, DOI 10.1002/hep.510230122
  5. Carvalho Grazielle Cerqueira de, 2012, Ann Hepatol, V11, P90
  6. Dobre M, 2011, INT UROL NEPHROL, V43, P175, DOI 10.1007/s11255-010-9725-8
  7. Duvoux C, 2002, HEPATOLOGY, V36, P374, DOI 10.1053/jhep.2002.34343
  8. Ghosh S, 2013, LIVER INT, V33, P1187, DOI 10.1111/liv.12179
  9. GINES A, 1993, GASTROENTEROLOGY, V105, P229
  10. Gluud LL, 2012, COCHRANE DB SYST REV, V9, DOI 10.1002/14651858.CD005162.PUB3
  11. Higgins Julian P T, 2011, BMJ, V343, pd5928, DOI 10.1136/bmj.d5928
  12. Hiremath SB, 2013, INDIAN J PHARMACOL, V45, P54, DOI 10.4103/0253-7613.106436
  13. Kiszka-Kanowitz M, 2004, SCAND J GASTROENTERO, V39, P486, DOI 10.1080/00365520310008728
  14. Liberati A, 2009, BMJ-BRIT MED J, V339, DOI 10.1136/bmj.b2700
  15. Martin-Llahi M, 2008, GASTROENTEROLOGY, V134, P1352, DOI 10.1053/j.gastro.2008.02.024
  16. Narahara Y, 2009, J GASTROEN HEPATOL, V24, P1791, DOI 10.1111/j.1440-1746.2009.05873.x
  17. Nazar A, 2010, HEPATOLOGY, V51, P219, DOI 10.1002/hep.23283
  18. Salerno F, 2011, J HEPATOL, V55, P1241, DOI 10.1016/j.jhep.2011.03.012
  19. Salerno F, 2007, GUT, V56, P1310, DOI 10.1136/gut.2006.107789
  20. Sanyal AJ, 2008, GASTROENTEROLOGY, V134, P1360, DOI 10.1053/j.gastro.2008.02.014
  21. Sharma P, 2008, AM J GASTROENTEROL, V103, P1689, DOI 10.1111/j.1572-0241.2008.01828.x
  22. Singh V, 2012, J HEPATOL, V56, P1293, DOI 10.1016/j.jhep.2012.01.012
  23. Wallace BC, 2009, BMC MED RES METHODOL, V9, DOI 10.1186/1471-2288-9-80